Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: An observational cohort study based on SEER-medicare

Robert I. Griffiths, Michelle L. Gleeson, Joseph R Mikhael, Mark D. Danese

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly. Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line CHOP (cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P)) or CVP +/- rituximab. Multivariate regression was used to estimate adjusted cumulative cost and survival differences between the two groups over four years after beginning treatment. The median age was 73 years (minimum 66 years), 56% had stage III-IV disease, and 67% received rituximab. Adding rituximab to first-line chemotherapy was associated with higher adjusted incremental total cost ($18,695; 95% Confidence Interval (CI) $9,302$28,643) and longer adjusted cumulative survival (0.18 years; 95% CI 0.100.27) over four years of followup. The expected cost-effectiveness was $102,142 (95% CI $34,531296, 337) per life-year gained. In routine clinical practice, adding rituximab to first-line chemotherapy for elderly patients with FL results in higher direct medical costs to Medicare and longer cumulative survival after four years.

Original languageEnglish (US)
Article number978391
JournalJournal of Cancer Epidemiology
DOIs
StatePublished - 2012

Fingerprint

Follicular Lymphoma
Medicare
Cost-Benefit Analysis
Observational Studies
Epidemiology
Cohort Studies
Costs and Cost Analysis
Drug Therapy
Survival
Confidence Intervals
Information Storage and Retrieval
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Registries
Rituximab

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health
  • Genetics

Cite this

@article{2df7f475ce3e41fab8d20497393dcceb,
title = "Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: An observational cohort study based on SEER-medicare",
abstract = "Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly. Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line CHOP (cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P)) or CVP +/- rituximab. Multivariate regression was used to estimate adjusted cumulative cost and survival differences between the two groups over four years after beginning treatment. The median age was 73 years (minimum 66 years), 56{\%} had stage III-IV disease, and 67{\%} received rituximab. Adding rituximab to first-line chemotherapy was associated with higher adjusted incremental total cost ($18,695; 95{\%} Confidence Interval (CI) $9,302$28,643) and longer adjusted cumulative survival (0.18 years; 95{\%} CI 0.100.27) over four years of followup. The expected cost-effectiveness was $102,142 (95{\%} CI $34,531296, 337) per life-year gained. In routine clinical practice, adding rituximab to first-line chemotherapy for elderly patients with FL results in higher direct medical costs to Medicare and longer cumulative survival after four years.",
author = "Griffiths, {Robert I.} and Gleeson, {Michelle L.} and Mikhael, {Joseph R} and Danese, {Mark D.}",
year = "2012",
doi = "10.1155/2012/978391",
language = "English (US)",
journal = "Journal of Cancer Epidemiology",
issn = "1687-8558",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients

T2 - An observational cohort study based on SEER-medicare

AU - Griffiths, Robert I.

AU - Gleeson, Michelle L.

AU - Mikhael, Joseph R

AU - Danese, Mark D.

PY - 2012

Y1 - 2012

N2 - Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly. Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line CHOP (cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P)) or CVP +/- rituximab. Multivariate regression was used to estimate adjusted cumulative cost and survival differences between the two groups over four years after beginning treatment. The median age was 73 years (minimum 66 years), 56% had stage III-IV disease, and 67% received rituximab. Adding rituximab to first-line chemotherapy was associated with higher adjusted incremental total cost ($18,695; 95% Confidence Interval (CI) $9,302$28,643) and longer adjusted cumulative survival (0.18 years; 95% CI 0.100.27) over four years of followup. The expected cost-effectiveness was $102,142 (95% CI $34,531296, 337) per life-year gained. In routine clinical practice, adding rituximab to first-line chemotherapy for elderly patients with FL results in higher direct medical costs to Medicare and longer cumulative survival after four years.

AB - Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly. Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line CHOP (cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P)) or CVP +/- rituximab. Multivariate regression was used to estimate adjusted cumulative cost and survival differences between the two groups over four years after beginning treatment. The median age was 73 years (minimum 66 years), 56% had stage III-IV disease, and 67% received rituximab. Adding rituximab to first-line chemotherapy was associated with higher adjusted incremental total cost ($18,695; 95% Confidence Interval (CI) $9,302$28,643) and longer adjusted cumulative survival (0.18 years; 95% CI 0.100.27) over four years of followup. The expected cost-effectiveness was $102,142 (95% CI $34,531296, 337) per life-year gained. In routine clinical practice, adding rituximab to first-line chemotherapy for elderly patients with FL results in higher direct medical costs to Medicare and longer cumulative survival after four years.

UR - http://www.scopus.com/inward/record.url?scp=84866245288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866245288&partnerID=8YFLogxK

U2 - 10.1155/2012/978391

DO - 10.1155/2012/978391

M3 - Article

C2 - 22969803

AN - SCOPUS:84866245288

JO - Journal of Cancer Epidemiology

JF - Journal of Cancer Epidemiology

SN - 1687-8558

M1 - 978391

ER -